A multicenter, 3-arm, open-label, phase IIa clinical trial to evaluate the safety and efficacy of tanibirumab (VEGFR2 mAb), in patients with recurrent glioblastoma (GBM). Conference Paper uri icon

authors

  • Cher, Lawrence
  • Nowak, Anna K
  • Iatropoulos, Georgios
  • Lee, Weon Sup
  • Lee, Seon Young
  • Shim, Sang Ryeol
  • Yoo, Jin San

publication date

  • 2017